January 31, 2012, Updated February 10, 2014

Israeli biopharmaceutical firm NasVax has attained provisional approval for nearly $1 million in grant money from the Office of the Chief Scientist.

The grant to NasVax – which develops improved vaccines and immunotherapeutic products – will be divided. Some $460,000 will be used for NasVax’s overseas R&D plan and almost $490,000 will be invested in its R&D in Israel.

NasVax is developing improved vaccines and immunotherapies to treat fatty liver disease and other inflammatory diseases.

In 2011, NasVax announced the success of a Phase 2a clinical trial of a new oral immunotherapy for non-alcoholic steatohepatitis (NASH), an inflammatory disease associated with fatty liver disease and the metabolic syndrome.

NasVax works in four areas: inflammatory and auto-immune diseases; Alzheimer’s disease; pneumococcal vaccines; and enhancing the immunogenicity of vaccines and immunotherapeutics.



Fighting for Israel's truth

We cover what makes life in Israel so special — it's people. A non-profit organization, ISRAEL21c's team of journalists are committed to telling stories that humanize Israelis and show their positive impact on our world. You can bring these stories to life by making a donation of $6/month. 

Jason Harris

Jason Harris

Executive Director

Read more: